Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled study of NS-136 in schizophrenia
CTR20253838Phase 2Active
- Sponsor
- Nuance Pharma
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NS-136 in schizophrenia, sponsored by Nuance Pharma. Started Nov 2025; status: active.
02
Drugs
NS-136
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20253838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253838.